In this episode, Nir Barzilai, director of the Institute for Aging Research and expert in the genetics of longevity, discusses the evidence that metformin and rapamycin have anti-aging properties and how his TAME study aims to support this hypothesis in humans. Additionally, he describes the role of genetics in lifespan/healthspan and how it might affect important pathways such as IGF and insulin sensitivity. We discuss: Nir’s background and interest in aging and endocrinology [3:30]; History of metformin, and understanding the mechanism [11:15]; Attempting to define insulin resistance [21:15]; Metformin as a possible anti-aging drug [48:45]; The TAME trial: Targeting Aging with MEtformin [57:45]; Why Nir believes metformin can slow aging [1:16:30]; The genetic gift of centenarians [1:28:00]; IGF/GH and its impact on aging and chronic diseases [1:34:15]; Genetics/epigenetics of centenarians, gene sequencing, CETP-VV, Lp(a) [1:49:15]; Should you be taking HGH? [2:05:30]; NAD and NAD precursors (NR and NMN) [2:30:00]; Parting thoughts on metformin [2:36:15]; Possible blind spots in Nir and Peter’s thinking? [2:43:00]; and More. Learn more at www.PeterAttiaMD.com Connect with Peter on Facebook | Twitter | Instagram.